Please login to the form below

Not currently logged in
Email:
Password:

GlycoVaxyn

This page shows the latest GlycoVaxyn news and features for those working in and with pharma, biotech and healthcare.

GSK buys vaccine specialist GlycoVaxyn for $190m

GSK buys vaccine specialist GlycoVaxyn for $190m

GSK buys vaccine specialist GlycoVaxyn for $190m. Acquisition will expand GSK’ s early vaccines pipeline. ... GlaxoSmithKline (GSK) has taken control of Swiss company GlycoVaxyn in a $190m deal that bolsters its early vaccines pipeline.

Latest news

  • Janssen boosts vaccines pipeline with GlycoVaxyn deal

    Janssen boosts vaccines pipeline with GlycoVaxyn deal. Research will focus on targeting multiple bacterial pathogens. ... Janssen has agreed a deal with Swiss vaccines specialist GlycoVaxyn to research and develop a vaccine for multiple bacterial

More from news
Approximately 2 fully matching, plus 0 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

  • GlycoVaxyn appoints Gerd Zettlmeissl as chairman GlycoVaxyn appoints Gerd Zettlmeissl as chairman

    GlycoVaxyn appoints Gerd Zettlmeissl as chairman. He will join the Swiss vaccines company in June. ... Swiss vaccines company GlycoVaxyn has appointed Gerd Zettlmeissl as chairman of the board of directors with effect from June, when he will take over

More from appointments
Approximately 1 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
An agency called Owen

We’re an independent brand and marketing agency that believes our DNA is a little different from others. * A respectful,...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics